ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sawai Pharmaceutical Co., Ltd.

Business Summary

Sawai Pharmaceutical Co., Ltd. engages in the manufacture and sale of prescription pharmaceutical products. Its products include cardiovascular drugs, antihyperlipidemic agents, diabetes, anticancer drugs, and over-the-counter drugs. The company was founded by Hanpei Sawai and Noyo Sawai on April 1, 1929 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue182,537M1,678.87M
Gross Profit73,500M676.01M
Operating income26,638M245.00M
Income before tax26,497M243.70M
Net income19,279M177.31M
EBITDA44,592M410.13M
Diluted EPS439.974.04
Dividends Per Share1301.19
Total Assets384,814M3,564.57M
Total liabilities151,128M1,399.91M
Total equity210,000M1,945.25M
Operating cash flow30,256M278.27M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 123,492M 132,392M 168,068M 184,341M 182,537M
Gross Profit 50,809M 50,922M 65,195M 69,726M 73,500M
Operating income 23,185M 23,347M 22,176M 25,848M 26,638M
Income before tax 23,091M 22,757M 20,251M 25,666M 26,497M
Net income 17,155M 17,969M 14,017M 19,376M 19,279M
EBITDA 30,229M 31,867M 36,415M 42,128M 44,592M
Diluted EPS 465.24 487.09 360.26 442.33 439.97
Dividends Per Share 120 130 130 135 130
Total Assets 206,492M 225,609M 358,453M 372,889M 384,814M
Total liabilities 80,772M 84,372M 156,011M 149,683M 151,128M
Total equity 125,720M 141,237M 181,350M 199,250M 210,000M
Operating cash flow 19,975M 23,270M 28,472M 42,923M 30,256M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 1,028.37M 1,222.59M 1,516.41M 1,662.30M 1,678.87M
Gross Profit 423.11M 470.24M 588.23M 628.75M 676.01M
Operating income 193.07M 215.60M 200.08M 233.08M 245.00M
Income before tax 192.28M 210.15M 182.71M 231.44M 243.70M
Net income 142.85M 165.93M 126.47M 174.72M 177.31M
EBITDA 251.73M 294.28M 328.55M 379.89M 410.13M
Diluted EPS 3.87 4.49 3.25 3.98 4.04
Dividends Per Share 0.99 1.20 1.17 1.21 1.19
Total Assets 1,837.19M 2,024.67M 3,370.50M 3,368.92M 3,564.57M
Total liabilities 718.64M 757.17M 1,466.95M 1,352.33M 1,399.91M
Total equity 1,118.55M 1,267.49M 1,705.21M 1,800.15M 1,945.25M
Operating cash flow 166.34M 214.89M 256.89M 387.06M 278.27M

Valuation Measures

Mar 2020
PER13.10
ROA5.08%
ROE9.42%
Operating margin14.59%
Profit margin10.56%

Key executives

  • President & Representative Director: Kenzo Sawai
  • Managing Executive Officer, General Manager-R&D: Shoji Yokota
  • Executive Officer & General Manager-Sales: Seiji Nishimura
  • Director & General Manager-Administration: Kazuhiko Sueyoshi
  • Senior Executive Officer: Kyozo Inari

Shareholders

  • LSV Asset Management (5.0%)
  • The Vanguard Group, Inc. (2.8%)
  • Nomura Asset Management Co., Ltd. (2.8%)
  • SAWAI HIROYUKI FAMILY (2.2%)
  • Azimut Capital Management SGR SpA (2.2%)
  • SAWAI MITSUO (2.1%)
  • SAWAI KENZO (1.9%)
  • Daiwa Asset Management Co. Ltd. (1.4%)
  • Sumitomo Corp. (1.4%)
  • SAWAI HIROYUKI (1.4%)

Contact Details

  • Website:http://www.sawai.co.jp
  • Address: 5-2-30 Miyahara, Yodogawa-Ku, Osaka, 532-0003, Japan
  • Phone: +81.6.6105.5711

Related Companies

  • Sawai America, Inc.
  • Sawai USA, Inc.
  • Mitsubishi Tanabe Pharma Factory Ltd. /Kashima Factory/
  • Sawai Pharmaceutical Employee Incentive Plan
  • Km Godo Kaisha
  • Kaken Shoyaku KK
  • Medisa Shinyaku, Inc.
  • Nihon Schering KK /Mobara Factory Operations/

Competitors

  • Xenon Pharmaceuticals Inc.
  • Antares Pharma, Inc.
  • Aeglea BioTherapeutics Inc
  • Albireo Pharma, Inc.
  • Lipocine Inc
  • Mirum Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.
  • X4 Pharmaceuticals, Inc.
  • Zosano Pharma Corp.
Last Updated on 3 Jul, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media